Tag: VistaGen Therapeutics
February 13, 2019
VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
VistaGen Therapeutics (NASDAQ:VTGN) has announced that the US Patent and Trademark Office (USPTO) has provided a notice of allowance for... November 29, 2018
VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101
VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with... October 25, 2018
VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10
VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system diseases and disorders with high unmet... October 3, 2018
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with... September 13, 2018
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals
VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS)... April 10, 2018
VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101
VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today... April 5, 2018